Natural killer cells and natural killer t cells

Arthritis and Rheumatism

Volumn 43, Issue 6, 2000, Pages 1204-1217

  Seaman, William E ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; INTERLEUKIN RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

APOPTOSIS; AUTOIMMUNITY; BONE MARROW TRANSPLANTATION; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; HOST RESISTANCE; HUMAN; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR REJECTION;

ANIMALS; AUTOIMMUNITY; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIESIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNITY; KILLER CELLS, NATURAL; PREGNANCY; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0034091432     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200006)43:6<1204::AID-ANR3>3.0.CO;2-I     Document Type: Review

References (183)

1. Kiessling R, Klein E, Wigzell H. "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells: specificity and distribution according to genotype. Eur J Immunol 1975;5:112-7.
2. Kiessling R, Klein E, Pross H, Wigzell H. "Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells: characteristics of the killer cell. Eur J Immunol 1975;5:117-21.
3. Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer 1975;16:216-29.
4. Herberman RB, Nunn ME, Holden HT, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer 1975;16:230-9.
5. West WH, Cannon GB, Kay HD, Bonnard GD, Herberman RB. Natural cytotoxic reactivity of human lymphocytes against a myeloid cell line: characterization of effector cells. J Immunol 1977;118:355-61.
6. Dorshkind K, Pollack SB, Bosma MJ, Phillips RA. Natural killer (NK) cells are present in mice with severe combined immunodeficiency (scid). J Immunol 1985;134:3798-801.
7. Shinkai Y, Rathbun G, Lam KP, Oltz EM, Stewart V, Mendelsohn M, et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 1992;68: 855-67.
8. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 1992;68:869-77.
9. Roberts K, Lotze MT, Rosenberg SA. Separation and functional studies of the human lymphokine-activated killer cell. Cancer Res 1987;47:4366-71.
10. Handa K, Suzuki R, Matsui H, Shimizu Y, Kumagai K. Natural killer (NK) cells as a responder to interleukin 2 (IL 2). II. IL 2-induced interferon gamma production. J Immunol 1983;130: 988-92.
11. Cuturi MC, Anegon I, Sherman F, Loudon R, Clark SC, Perussia B, et al. Production of hematopoietic colony-stimulating factors by human natural killer cells. J Exp Med 1989;169:569-83.
12. Degliantoni G, Murphy M, Kobayashi M, Francis MK, Perussia B, Trinchieri G. Natural killer (NK) cell-derived hematopoietic colony-inhibiting activity and NK cytotoxic factor: relationship with tumor necrosis factor and synergism with immune interferon. J Exp Med 1985;162:1512-30.
13. + T and NK cells. J Exp Med 1994;180:1937-42.
14. Warren HS, Kinnear BF, Phillips JH, Lanier LL. Production of IL-5 by human NK cells and regulation of IL-5 secretion by IL-4, IL-10, and IL-12. J Immunol 1995;154:5144-52.
15. Mehrotra PT, Donnelly RP, Wong S, Kanegane H, Geremew A, Mostowski HS, et al. Production of IL-10 by human natural killer cells stimulated with IL-2 and/or IL-12. J Immunol 1998;160: 2637-44.
16. Hoshino T, Winkler-Pickett RT, Mason AT, Ortaldo JR, Young HA. IL-13 production by NK cells: IL-13-producing NK and T cells are present in vivo in the absence of IFN-γ. J Immunol 1999;162:51-9.
17. Salvucci O, Mami-Chouaib F, Moreau JL, Theze J, Chehimi J, Chouaib S. Differential regulation of interleukin-12- and interleukin-15-induced natural killer cell activation by interleukin-4. Eur J Immunol 1996;26:2736-41.
18. Peritt D, Robertson S, Gri G, Showe L, Aste-Amezaga M, Trinchieri G. Cutting edge: differentiation of human NK cells into NK1 and NK2 subsets. J Immunol 1998;161:5821-4.
19. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokincs. Annu Rev Immunol 1999;17:189-220.
20. Unanue ER. Inter-relationship among macrophages, natural killer cells and ncutrophils in early stages of Listeria resistance. Curr Opin Immunol 1997;9:35-43.
21. Perussia B, Trinchieri G, Jackson A, Warner NL, Faust J, Rumpold H, et al. The Fc receptor for IgG on human natural killer cells: phenotypic, functional, and comparative studies with monoclonal antibodies. J Immunol 1984;133:180-9.
22. Ojo E, Wigzell H. Natural killer cells may be the only cells in normal mouse lymphoid cell populations endowed with cytolytic ability for antibody-coated tumour target cells. Scand J Immunol 1978;7:297-306.
23. Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 1986;136:4480-6.
24. Lanier LL, Chang C, Azuma M, Ruitenberg JJ, Hemperly JJ, Phillips JH. Molecular and functional analysis of human natural killer cell-associated neural cell adhesion molecule (N-CAM/ CD56). J Immunol 1991;146:4421-6.
25. Nagler A, Lanier LL, Cwirla S, Phillips JH. Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol 1989;143:3183-91.
26. Garni-Wagner BA, Purohit A, Mathew PA, Bennett M, Kumar V. A novel function-associated molecule related to non-MHC-restricted cytotoxicity mediated by activated natural killer cells and T cells. J Imnnmol 1993;151:60-70.
27. Boles KS, Nakajima H, Colonna M, Chuang SS, Stepp SE, Bennett M, et al. Molecular characterization of a novel human natural killer cell receptor homologous to mouse 2B4. Tissue Antigens 1999;54:27-34.
28. Nakajima H, Cella M, Langen H, Friedlein A, Colonna M. Activating interactions in human NK cell recognition: the role of 2B4-CD48. Eur J Immunol 1999;29:1676-83.
29. Brown MH, Boles K, van der Merwe PA, Kumar V, Mathew PA, Barclay AN. 2B4, the natural killer and T cell immunoglobulin superfamily surface protein, is a ligand for CD48. J Exp Med 1998;188:2083-90.
30. Schatzle JD, Sheu S, Stepp SE, Mathew PA, Bennett M, Kumar V. Characterization of inhibitory and stimulatory forms of the murine natural killer cell receptor 2B4. Proc Natl Acad Sci U S A 1999;96:3870-5.
31. Sivori S, Vitale M, Morelli L, Sanseverino L, Augugliaro R, Bottino C, et al. p46, a novel natural killer cell-specific surface molecule that mediates cell activation. J Exp Med 1997;186: 1129-36.
32. Pende D, Parolini S, Pessino A, Sivori S, Augugliaro R, Morelli L, et al. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 1999;190:1505-16.
33. Vitale M, Bottino C, Sivori S, Sanseverino L, Castriconi R, Marcenaro E, et al. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med 1998;187:2065-72.
34. Perussia B. The cytokine profile of resting and activated NK cells. Methods 1996;9:370-8.
35. Kehri JH, Dukovich M, Whalen G, Katz P, Fauci AS, Greene WC. Novel interleukin 2 (IL-2) receptor appears to mediate IL-2-induced activation of natural killer cells. J Clin Invest 1988;81:200-5.
36. Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R, et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 1994;180:1395-403.
37. Williams NS, Klem J, Puzanov IJ, Sivakumar PV, Schatzle JD, Bennett M, et al. Natural killer cell differentiation: insights from knockout and transgenic mouse models and in vitro systems. Immunol Rev 1998;165:47-61.
38. Fawaz LM, Sharif-Askari E, Menezes J. Up-regulation of NK cytotoxic activity via IL-15 induction by different viruses: a comparative study. J Immunol 1999;163:4473-80.
39. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995;378:88-91.
40. Ushio S, Namba M, Okura T, Hattori K, Nukada Y, Akita K, et al. Cloning of the cDNA for human IFN-γ-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. J Immunol 1996;156:4274-9.
41. Takeda K, Tsutsui H, Yoshimoto T, Adachi O, Yoshida N, Kishimoto T, et al. Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity 1998;8:383-90.
42. Puccetti P, Santoni A, Riccardi C, Herberman RB. Cytotoxic effector cells with the characteristics of natural killer cells in the lungs of mice. Int J Cancer 1980;25:153-8.
43. Shanahan F, Brogan M, Targan S. Human mucosal cytotoxic effector cells. Gastroenterology 1987;92:1951-7.
44. Wisse E, Luo D, Vermijlen D, Kanellopoulou C, De Zanger R, Braet F. On the function of pit cells, the liver-specific natural killer cells. Semin Liver Dis 1997;17:265-86.
45. Norris S, Doherty DG, Collins C, McEntee G, Traynor O, Hegarty JE, et al. Natural T cells in the human liver: cytotoxic lymphocytes with dual T cell and natural killer cell phenotype and function are phenotypically heterogenous and include Valpha24-JalphaQ and gammadelta T cell receptor hearing cells. Hum Immunol 1999;60:20-31.
46. Rolstad B, Herberman RB, Reynolds CW. Natural killer cell activity in the rat. V. The circulation patterns and tissue localization of peripheral blood large granular lymphocytes (LGL). J Immunol 1986;136:2800-81.
47. King A, Burrows T, Verma S, Hiby S, Loke YW. Human uterine lymphocytes. Hum Reprod Update 1998;4:480-5.
48. Starkey PM. Natural killer cells/large granular lymphocytes in pregnancy. In: Lewis CE, McGee JO, editors. The natural killer cell. New York: Oxford University Press; 1992. p. 205-40.
49. Seaman WE, Sleisenger M, Eriksson E, Koo GC. Depletion of natural killer cells in mice by monoclonal antibody to NK-1.1: reduction in host defense against malignancy without loss of cellular or humoral immunity. J Immunol 1987;138:4539-44.
50. Lotze MT, Custer MC, Bolton ES, Wiebke EA, Kawakami Y, Rosenberg SA. Mechanisms of immunologic antitumor therapy: lessons from the laboratory and clinical applications. Hum Immunol 1990;28:198-207.
51. Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med 1989; 320:1731-5.
52. Salazar-Mather TP, Orange JS, Biron CA. Early murine cytomegalovirus (MCMV) infection induces liver natural killer (NK) cell inflammation and protection through macrophage inflammatory protein 1alpha (MIP-1alpha)-dependent pathways. J Exp Med 1998;187:1-14.
53. Lathbury LJ, Allan JE, Shellam GR, Scalzo AA. Effect of host genotype in determining the relative roles of natural killer cells and T cells in mediating protection against murine cytomegalovirus infection. J Gen Virol 1996;77:2605-13.
54. Tripp CS, Wolf SF, Unanue ER. Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc Natl Acad Sci USA 1993;90:3725-9.
55. Fehniger TA, Shah MH, Turner MJ, VanDeusen JB, Whitman SP, Cooper MA, et al. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol 1999;162:4511-20.
56. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996;17:138-46.
57. Coffman RL, Mocci S, O'Garra A. The stability and reversibility of Th1 and Th2 populations. Curr Top Microbiol Immunol 1999;238:1-12.
58. Wakil AE, Wang ZE, Ryan JC, Fowell DJ, Locksley RM. Interferon gamma derived from CD4(+) T cells is sufficient to mediate T helper cell type 1 development. J Exp Med 1998;188: 1651-6.
59. Walker C, Checkel J, Cammisuli S, Leibson PJ, Gleich GJ. IL-5 production by NK cells contributes to eosinophil infiltration in a mouse model of allergic inflammation. J Immunol 1998;161: 1962-9.
60. Korsgren M, Persson CG, Sundler F, Bjerke T, Hansson T, Chambers BJ, et al. Natural killer cells determine development of allergen-induced eosinophilic airway inflammation in mice. J Exp Med 1999;189:553-62.
61. Biron CA. Initial and innate responses to viral infections -pattern setting in immunity or disease. Curr Opin Microbiol 1999;2:374-81.
62. Kiessling R, Hochman PS, Haller O, Shearer GM, Wigzell H, Cudkowicz G. Evidence for a similar or common mechanism for natural killer cell activity and resistance to hemopoietic grafts. Eur S Immunol 1977;7:655-63.
63. Rolstad B, Fossum S, Bazin H, Kimber I, Marshall J, Sparshott SM, et al. The rapid rejection of allogeneic lymphocytes by a non-adaptive, cell-mediated mechanism (NK activity). Immunology 1985;54:127-38.
64. George T, Yu YY, Liu J, Davenport C, Lemieux S, Stoneman E, et al. Allorecognition by murine natural killer cells: lysis of T-lymphoblasts and rejection of bone-marrow grafts. Immunol Rev 1997;155:29-40.
65. Neipp M, Gammie JS, Exner BG, Li S, Chambers WH, Pham SM, et al. A partial conditioning approach to achieve mixed chimerism in the rat: depiction of host natural killer cells significantly reduces the amount of total body irradiation required for engraftment. Transplantation 1999;68:369-78.
66. Bix M, Liao NS, Zijlstra M, Loring J, Jaenisch R, Raulet D. Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice. Nature 1991;349:329-31.
67. Baker MB, Podack ER, Levy RB. Perforin- and Fas-mediated cytotoxic pathways are not required for allogeneic resistance to bone marrow grafts in mice. Biol Blood Marrow Transplant 1995;1:69-73.
68. Manilay JO, Sykes M. Natural killer cells and their role in graft rejection. Curr Opin Immunol 1998;10:532-8.
69. Tefferi A, Li CY, Witzig TE, Dhodapkar MV, Okuno SH, Phyliky RL. Chronic natural killer cell lymphocytosis: a descriptive clinical study. Blood 1994;84:2721-5.
70. Kingreen D, Siegert W. Chronic lymphatic leukemias of T and NK cell type. Leukemia 1997;11 Suppl 2:S46-9.
71. Loughran TP Jr, Starkebaum G, Kidd P, Neiman P. Clonal proliferation of large granular lymphocytes in rheumatoid arthritis. Arthritis Rheum 1988;31:31-6.
72. Handgretinger R, Geiselhart A, Moris A, Grau R, Teuffel O, Bethge W, et al. Pure red-cell aplasia associated with clonal expansion of granular lymphocytes expressing killer-cell inhibitory receptors. N Engl J Med 1999;340:278-84.
73. Rabbani GR, Phyliky RL, Tefferi A. A long-term study of patients with chronic natural killer cell lymphocytosis. Br J Haematol 1999;106:960-6.
74. Kwong YL, Chan AC, Liang R, Chiang AK, Chim CS, Chan TK, et al. CD56+ NK lymphomas: clinicopathological features and prognosis. Br J Haematol 1997;97:821-9.
75. Chiang AK, Chan AC, Srivastava G, Ho FC. Nasal T/natural killer (NK)-cell lymphomas are derived from Epstein-Barr virus-infected cytotoxic lymphocytes of both NK- and T-cell lineage. Int J Cancer 1997;73:332-8.
76. Lopez C, Kirkpatrick D, Sorell M, O'Reilly RJ, Ching C. Association between pro-transplant natural kill and graft-versus-host disease after stem-cell transplantation. Lancet 1979;2: 1103-7.
77. MacDonald GC, Gartner JG. Prevention of acute lethal graft-versus-host disease in F1 hybrid mice by pretreatment of the graft with anti-NK-1.1 and complement. Transplantation 1992;54:147-52.
78. Asai O, Longo DL, Tian Z-G, Hornung RL, Taub DD, Ruscetti FW, et al. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest 1998;101:1835-42.
79. Zeng D, Lewis D, Dejbakhsh-Jones S, Lan F, Garcia-Ojeda M, Sibley R, et al. Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease. J Exp Med 1999;189:1073-81.
80. King A, Loke YW. The influence of the maternal uterine immune response on placentation in human subjects. Proc Nutr Soc 1999;58:69-73.
81. De Fougerolles AR, Baines MG. Modulation of the natural killer cell activity in pregnant mice alters the spontaneous abortion rate. J Reprod Immunol 1987;11:147-153.
82. Guimond M, Wang B, Croy BA. Immune competence involving the natural killer cell lineage promotes placental growth. Placenta 1999;20:441-50.
83. + T cells in a transfer model of colitis. J Immunol 1998;161:3256-61.
84. Zhang B, Yamamura T, Kondo T, Fujiwara M, Tabira T. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J Exp Med 1997;186:1677-87.
85. Sibbitt WL Jr, Bankhurst AD. Natural killer cells in connective tissue disorders. Clin Rheum Dis 1985;11:507-21.
86. Negishi K, Waldeck N, Chandy G, Buckingham B, Kershnar A, Fisher L, et al. Natural killer cell and islet killer cell activities in type 1 (insulin-dependent) diabetes. Diabetologia 1986;29:352-7.
87. Chiang BL, Chen YC, Wang CR, Lin YL, Chou CC, Hsieh KH. Phenotypic and functional analysis of natural killer cells in systemic lupus crythematosus patients. Chung Hua Min Kuo Hsiao Erh Ko I Hsueh Hui Tsa Chih 1995;36:357-63.
88. Nagao F, Yabe T, Xu M, Okumura K. Phenotypical and functional analyses of natural killer cells from low NK activity individuals among healthy and patient populations. Nat Immun 1995;14:225-33.
89. Yabuhara A, Yang F-C, Nakazawa T, Iwasaki Y, Mori T, Koike K, et al. A killing defect of natural killer cells as an underlying immunologic abnormality in childhood systemic lupus erythematosus. J Rheumatol 1996;23:171-7.
90. Hussain MJ, Alviggi L, Millward BA, Leslie RD, Pyke DA, Vergani D. Evidence that the reduced number of natural killer cells in type 1 (insulin-dependent) diabetes may be genetically determined. Diabetologia 1987;30:907-11.
91. Garcia-Suarez J, Prieto A, Reyes E, Manzano L, Merino JL, Alvarez-Mon M. Severe chronic autoimmune thrombocytopenic purpura is associated with an expansion of CD56+ CD3-natural killer cell subset. Blood 1993;82:1538-45.
92. Tak PP, Kummer JA, Hack CE, Daha MR, Smeets TJ, Erkelens GW, et al. Granzyme-positive cytotoxic cells are specifically increased in early rheumatoid synovial tissue. Arthritis Rheum 1994;37:1735-43.
93. Tak PP, Spaeny-Dekking L, Kraan MC, Breedveld FC, Froelich CJ, Hack CE. The levels of soluble granzyme A and B are elevated in plasma and synovial fluid of patients with rheumatoid arthritis (RA). Clin Exp Immunol 1999;116:366-70.
94. Vyakarnam A, Brenner MK, Reittie JE, Houlker CH, Lachmann PJ. Human clones with natural killer function can activate B cells and secrete B cell differentiation factors. Eur J Immunol 1985; 15:606-10.
95. Brenner MK, Vyakarnam A, Reittie JE, Wimperis JZ, Grob JP, Hoffbrand AV, et al. Human large granular lymphocytes induce immunoglobulin synthesis after bone marrow transplantation. Eur J Immunol 1987;17:43-7.
96. Horwitz DA, Gray JD, Ohtsuka K. Role of NK cells and TGF-beta in the regulation of T-cell-dependent antibody production in health and autoimmune disease. Microb Infect 1999;1: 1305-11.
97. Itoh H, Abo T, Sugawara S, Kanno A, Kumagai K. Age-related variation in the proportion and activity of murine liver natural killer cells and their cytotoxicity against regenerating hepatocytes. J Immunol 1988;141:315-23.
98. Tamura F, Masuhara A, Sakaida I, Fukumoto E, Nakamura T, Okita K. FK506 promotes liver regeneration by suppressing natural killer cell activity. J Gastroenterol Hepatol 1998;13: 703-8.
99. Yao L, Sgadari C, Furuke K, Bloom ET, Teruya-Feldstein J, Tosato G. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood 1999;93:1612-21.
100. Podack ER. Perforin, killer cells and gene transfer immunotherapy for cancer. Curr Top Microbiol Immunol 1995;198:121-30.
101. Simon MM, Hausmann M, Tran T, Ebnet K, Tschopp J, ThaHla R, et al. In vitro- and ex vivo-derived cytolytic leukocytes from granzyme A x B double knockout mice are defective in granule-mediated apoptosis but not lysis of target cells. J Exp Med 1997;186:1781-6.
102. Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 1999;17:331-7.
103. Berke G. Killing mechanisms of cytotoxic lymphocytes. Curr Opin Hematol 1997;4:32-40.
104. Bossi G, Griffiths GM. Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells. Nat Med 1999;5:90-6.
105. Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, Perussia B. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med 1998;188:2375-80.
106. Ware CF, Crowe PD, Grayson MH, Androlewicz MJ, Browning JL. Expression of surface lymphotoxin and tumor necrosis factor on activated T, B, and natural killer cells. J Immunol 1992;149: 3881-8.
107. Kashii Y, Giorda R, Herberman RB, Whiteside TL, Vujanovic NL. Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells. J Immunol 1999;163:5358-66.
108. Smyth MJ, Kelly JM, Baxter AG, Korner H, Sedgwick JD. An essential role for tumor necrosis factor in natural killer cell-mediated tumor rejection in the peritoneum. J Exp Med 1998; 188:1611-9.
109. Kärre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986;319:675-8.
110. Hoglund P, Sundback J, Olsson-Alheim MY, Johansson M, Salcedo M, Ohlen C, et al. Host MHC class I gene control of NK-cell specificity in the mouse. Immunol Rev 1997;155:11-28.
111. Karlhofer FM, Ribaudo RK, Yokoyama WM. MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells. Nature 1992;358:66-70.
112. Ciccone E, Pende D, Viale O, Than A, Di Donato C, Orengo AM, et al. Involvement of HLA class I alleles in natural killer (NK) cell-specific functions: expression of HLA-Cw3 confers selective protection from lysis by alloreactive NK clones displaying a defined specificity (specificity 2). J Exp Med 1992;176:963-71.
113. Colonna M, Samaridis J. Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science 1995;268:405-8.
114. Wagtmann N, Biassoni R, Cantoni C, Verdiani S, Malnati MS, Vitale M, et al. Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains. Immunity 1995;2:439-49.
115. D'Andrea A, Chang C, Franz-Bacon K, McClanahan T, Phillips JH, Lanier LL. Molecular cloning of NKB1: a natural killer cell receptor for HLA-B allotypes. J Immunol 1995;155:2306-10.
116. Burshtyn DN, Scharenberg AM, Wagtmann N, Rajagopalan S, Berrada K, Yi T, et al. Recruitment of tyrosine phosphatase HCP by the killer cell inhibitor receptor. Immunity 1996;4:77-85.
117. Valiante NM, Uhrberg M, Shilling HG, Lienerl-Weidenbach K, Arnett KL, D'Andrea A, et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 1997;7:739-51.
118. Jimenez P, Canton J, Collado A, Cabrera T, Serrano A, Real LM, et al. Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors. Int J Cancer 1999;83:91-7.
119. Del Val M, Hengel H, Hacker H, Hartlaub U, Ruppert T, Lucin P, et al. Cytomegalovirus prevents antigen presentation by blocking the transport of peptide-loaded major histocompatibility complex class I molecules into the medial-Golgi compartment. J Exp Med 1992;176:729-38.
120. Yokoyama WM, Jacobs LB, Kanagawa O, Shevach EM, Cohen DI. A murine T lymphocyte antigen belongs to a supergene family of type II integral membrane proteins. J Immunol 1989; 143:1379-86.
121. Ryan JC, Seaman WE. Divergent functions of lectin-like receptors on NK cells. Immunol Rev 1997;155:79-89.
122. Long EO. Regulation of immune responses through inhibitory receptors. Annu Rev Immunol 1999;17:875-904.
123. Ciccone E, Pende D, Viale O, Di Donato C, Tripodi G, Orengo AM, et al. Evidence of a natural killer (NK) cell repertoire for (allo) antigen recognition: definition of five distinct NK-determined allospecificities in humans. J Exp Med 1992;175:709-18.
124. Colonna M, Brooks EG, Falco M, Ferrara GB, Strominger JL. Generation of allospecific natural killer cells by stimulation across a polymorphism of HLA-C. Science 1993;260:1121-4.
125. Gumperz JE, Litwin V, Phillips JH, Lanier LL, Parham P. The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med 1995;181:1133-44.
126. Biassoni R, Falco M, Cambiaggi A, Costa P, Verdiani S, Pende D, et al. Amino acid substitutions can influence the natural killer (NK)-mediated recognition of HLA-C molecules: role of serine-77 and lysine-80 in the target cell protection from lysis mediated by "group 2" or "group 1" NK clones. J Exp Med 1995;182:605-9.
127. Mingari MC, Schiavetti F, Ponte M, Vitale C, Maggi E, Romagnani S, et al. Human CD8+ T lymphocyte subsets that express HLA class I-specific inhibitory receptors represent oligoclonally or monoclonally expanded cell populations. Proc Natl Acad Sci USA 1996;93:12433-8.
128. Lopez-Botet M, Carretero M, Perez-Villar J, Bellon T, Llano M, Navarro F. The CD94/NKG2 C-type lectin receptor complex: involvement in NK cell-mediated recognition of HLA class I molecules. Immunol Res 1997;16:175-85.
129. Lazetic S, Chang C, Houchins JP, Lanier LL, Phillips JH. Human natural killer cell receptors involved in MHC class I recognition are disulfide-linked heterodimers of CD94 and NKG2 subunits. J Immunol 1996;157:4741-5.
130. Houchins JP, Lanier LL, Niemi EC, Phillips JH, Ryan JC. Natural killer cell cytolytic activity is inhibited by NKG2-A and activated by NKG2-C. J Immunol 1997;158:3603-9.
131. O'Callaghan CA, Tormo J, Willcox BE, Braud VM, Jakobsen BK, Stuart DI, et al. Structural features impose tight peptide binding specificity in the nonclassical MHC molecule HLA-E. Mol Cell 1998;1:531-41.
132. Braud VM, Allan DS, Wilson D, McMichael AJ. TAP- and tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide. Curr Biol 1998;8:1-10.
133. Braud VM, Allan DS, O'Callaghan CA, Soderstrom K, D'Andrea A, Ogg GS, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998;391:795-9.
134. Lee N, Llano M, Carretero M, Ishitani A, Navarro F, Lopez-Botet M, et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci U S A 1998;95:5199-204.
135. Moretta A, Sivori S, Vitale M, Pende D, Morelli L, Augugliaro R, et al. Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells. J Exp Med 1995;182:875-84.
136. Mason LH, Ortaldo JR, Young HA, Kumar V, Bennett M, Anderson SK. Cloning and functional characteristics of murine large granular lymphocyte-1: a member of the Ly-49 gene family (Ly-49G2). J Exp Med 1995;182:293-303.
137. Lanier LL, Corliss BC, Wu J, Leong C, Phillips JH. Immunoreceptor DAP12 hearing a tyrosine-based activation motif is involved in activating NK cells. Nature 1998;391:703-7.
138. Ponte M, Cantoni C, Biassoni R, Tradori-Cappai A, Bentivoglio G, Vitale C, et al. Inhibitory receptors sensing HLA-G1 molecules in pregnancy: decidua-associated natural killer cells express LIR-1 and CD94/NKG2A and acquire p49, an HLA-G1-specific receptor. Proc Natl Acad Sci U S A 1999;96:5674-9.
139. Houchins JP, Yabe T, McSherry C, Bach FH. DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integial membrane proteins on human natural killer cells. J Exp Med 1991;173:1017-20.
140. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999;285:727-9.
141. Yokoyama WM, Daniels BH, Seaman WE, Hunziker R, Margulies DH, Smith HR. A family of murine NK cell receptors specific for target cell MHC class I molecules. Semin Immunol 1995;7: 89-101.
142. Makrigiannis AP, Gosselin P, Mason LH, Taylor LS, McVicar DW, Ortaldo JR, et al. Cloning and characterization of a novel activating Ly49 closely related to Ly49A. J Immunol 1999;163: 4931-8.
143. Brown MG, Zhang J, Du Y, Stoll J, Yokoyama WM, Scalzo AA. Localization on a physical map of the NKC-linked Cmv1 locus between Ly49b and the Prp gene cluster on mouse chromosome 6. J Immunol 1999;163:1991-9.
144. Kumar V, George T, Yu YYL, Liu J, Bennett M. Role of murine NK cells and their receptors in hybrid resistance. Curr Opin Immunol 1997;9:52-56.
145. Valiante NM, Parham P. Natural killer cells, HLA class I molecules, and marrow transplantation. Biol Blood Marrow Transplant 1997;3:229-35.
146. Nakamura MC, Naper C, Niemi EC, Spusta SC, Rolstad B, Butcher GW, et al. Natural killing of xenogeneic cells mediated by the mouse Ly-49D receptor. J Immunol 1999;163:4694-700.
147. Glimcher L, Shen FW, Cantor H. Identification of a cell-surface antigen selectively expressed on the natural killer cell. J Exp Med 1977;145:1-9.
148. + and CD4 8 T cells in mice and humans. J Exp Med 1994;180:1097-106.
149. Bendelac A, Lantz O, Quimby ME, Yewdell JW, Bennink JR, Brutkiewicz RR. CD1 recognition by mouse NK1+ T lymphocytes. Science 1995;268:863-5.
150. Kawano T, Cui J, Koczuka Y, Toura I, Kaneko Y, Motoki K, et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997;278:1626-9.
151. Joyce S, Woods AS, Yewdell JW, Bennink JR, De Silva AD, Boesteanu A, et al. Natural ligand of mouse CD1d1: cellular glycosylphosphatidylinositol. Science 1998;279:1541-4.
152. Zeng Z, Castano AR, Segelke BW, Stura EA, Peterson PA, Wilson IA. Crystal structure of mouse CD1: an MHC-like fold with a large hydrophobic binding groove. Science 1997;277:339-45.
153. Naidenko OV, Maher JK, Ernst WA, Sakai T, Modlin RL, Kronenberg M. Binding and antigen presentation of ceramide-containing glycolipids by soluble mouse and human CD1d molecules. J Exp Med 1999;190:1069-80.
154. Lanier LL, Chang C, Phillips JH. Human NKR-PIA: a disulfide-linked homodimer of the C-type lectin superfamily expressed by a subset of NK and T lymphocytes. J Immunol 1994;153:2417-28.
155. Porcelli S, Yockey CE, Brenner MB, Balk SP. Analysis of T cell antigen receptor (TCR) expression by human peripheial blood CD4-8-alpha/beta T cells demonstrates preferential use of several V beta genes and an invariant TCR alpha chain. J Exp Med 1993;178:1-16.
156. Exley M, Garcia J, Balk SP, Porcelli S. Requirements for CD1d recognition by human invariant Valpha24+ CD4-CD8-T cells. J Exp Med 1997;186:109-20.
157. Porcelli S, Morita CT, Brenner MB. CD1b restricts the response of human CD4-8-T lymphocytes to a microbial antigen. Nature 1992;360:593-7.
158. Sieling PA, Chatterjee D, Porcelli SA, Prigozy TI, Mazzaccaro RJ, Soriano T, et al. CD1-restricted T cell recognition of microbial lipoglycan antigens. Science 1995;269:227-30.
159. Beckman EM, Melian A, Behar SM, Sieling PA, Chatterjee D, Furlong ST, et al. CD1c restricts responses of mycobacteria-specific T cells: evidence for antigen presentation by a second member of the human CD1 family. J Immunol 1996;157:2795-803.
160. Schofield L, McConville MJ, Hansen D, Campbell AS, Fraser-Reid B, Grusby MJ, et al. CD1d-restricted immunoglobulin G formation to GPI-anchored antigens mediated by NKT cells. Science 1999;283:225-9.
161. Gumperz JE, Roy C, Makowska A, Lum D, Sugita M, Podrebarac T, et al. Murine CD1d-resiricted T cell recognition of cellular lipids. Immunity 2000;12:211-2.
162. + NK T lymphocytes. J Immunol 1998;161:3271-81.
163. Arase H, Arase N, Saito T. Interferon gamma production by natural killer (NK) cells and NK1.1+ T cells upon NKR-P1 cross-linking. J Exp Med 1996;183:2391-6.
164. pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J Exp Med 1994;179:1285-95.
165. Yoshimoto T, Bendelac A, Watson C, Hu-Li J, Paul WE. Role of NK1.1+ T cells in a TH2 response and in immunoglobulin E production. Science 1995;270:1845-7.
166. + T cells in IL-12-induced immune responses in vivo. J Immunol 1998;160: 16-9.
167. Takeda K, Dennert G. The development of autoimmunity in C57BL/6 1pr mice correlates with the disappearance of natural killer type 1-positive cells: evidence for their suppressive action on bone marrow stem cell proliferation, B cell immunoglobulin secretion, and autoimmune symptoms. J Exp Med 1993;177:155-64.
168. Gombert JM, Herbelin A, Tancrede-Bohin E, Dy M, Carnaud C, Bach JF. Early quantitative and functional deficiency of NK1+-like thymocytes in the NOD mouse. Etir J Immunol 1996;26: 2989-98.
169. Godfrey DI, Kinder SJ, Silvera P, Baxter AG. Flow cytometric study of T cell development in NOD mice reveals a deficiency in alphabetaTCR+CDR-CD8-thymocytes. J Autoimmun 1997; 10:279-85.
170. Wilson SB, Kent SC, Patton KT, Orban T, Jackson RA, Exley M, et al. Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes [published erratum appears in Nature 1999;399: 84]. Nature 1998;391:177-81.
171. Baxter AG, Kinder SJ, Hammond KJ, Scollay R, Godfrey DI. Association between alphabetaTCR+CD4-CD8-T-cell deficiency and IDDM in NOD/Lt mice. Diabetes 1997;46:572-82.
172. Hammond KJL, Poulton LD, Palmisano LJ, Silveira PA, Godfrey DI, Baxter AG. Alpha/beta-T cell receptor (TCR)+CD4-CD8-(NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J Exp Med 1998;187:1047-56.
173. Lehuen A, Lantz O, Beaudoin L, Laloux V, Carnaud C, Bendelac A, et al. Overexpression of natural killer T cells protects Valpha14-Jalpha281 transgenic nonobese diabetic mice against diabetes. J Exp Med 1998;188:1831-9.
174. Rapoport MJ, Jaramillo A, Zipris D, Lazarus AH, Serreze DV, Leiter EH, et al. Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med 1993;178:87-99.
175. Falcone M, Yeung B, Tucker L, Rodriguez E, Sarvetnick N. A defect in interleukin 12-induced activation and interferon gamma secretion of peripheral natural killer T cells in nonobese diabetic mice suggests new pathogenic mechanisms for insulin-dependent diabetes mcllitus. J Exp Med 1999;190:963-72.
176. + NK T cells associated with disease development in autoimmune-prone mice. J Immunol 1996;156:4035-40.
177. Sumida T, Sakamoto A, Murata H, Makino Y, Takahashi H, Yoshida S, et al. Selective reduction of T cells bearing invariant Va24JαQ antigen receptor in patients with systemic sclerosis. J Exp Med 1995;182:1163-8.
178. Streilein JW, Ksander BR, Taylor AW. Immune deviation in relation to ocular immune privilege. J Immunol 1997;158:3557-60.
179. Sonoda KH, Exley M, Snapper S, Balk SP, Stein-Streilein J. CD1-reactivc natural killer T cells are required for development of systemic tolerance through an immune-privileged site. J Exp Med 1999;190:1215-26.
180. Cui J, Shin T, Kawano T, Sato H, Kondo E, Toura I, et al. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 1997;278:1623-6.
181. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Sato H, et al. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. Proc Natl Acad Sci U S A 1998;95:5690-3.
182. Toura I, Kawano T, Akutsu Y, Nakayama T, Ochiai T, Taniguchi M. Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with α-galactosylceramide. J Immunol 1999;163:2387-91.
183. Carnaud C, Lee D, Donnars O, Park S-H, Beavis A, Koezuka Y, et al. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol 1999;163: 4647-50.